



02 December 2019

Circular 045/19

Liraglutide (Victoza®)

Dear Pharmacist,

I refer to previous correspondence in relation to Liraglutide (Victoza®) and the prescribing information developed by the HSE Medicines Management Programme at that time (Circular 7/17). As Liraglutide (Victoza®) is indicated for the treatment of Type II Diabetes Mellitus, patients are entitled to be registered under the Long Term Illness (LTI) Scheme to enable them to obtain this product free of charge. The form can be downloaded at <https://www2.hse.ie/file-library/long-term-illness/long-term-illness-scheme-application-form.pdf>.

Therefore, **effective 1st December 2019**, reimbursement will be confined to those persons with full GMS and LTI eligibility. Reimbursement of Victoza® will not be made available under the Drugs Payment Scheme (DPS) from this date.

You are reminded that prescriptions for Liraglutide (Victoza®) at doses in excess of 1.8 mg daily are outside the licensed indication with a maximum quantity applied of one box (or 3 pens) per month. The facility is available to pharmacies for 13 dispensings' in a rolling 12 months to accommodate the shortfall.

Liraglutide (Saxenda®) which is licensed for weight management in adult patients is currently undergoing a pricing and reimbursement assessment with the National Centre for Pharmacoeconomics (NCPE). Any product that is undergoing a formal pharmacoeconomic assessment is not reimbursable under GMS and Community Drug Schemes.

Yours faithfully,

A handwritten signature in blue ink, appearing to read 'Shaun Flanagan'.

Shaun Flanagan
Primary Care Eligibility & Reimbursement Service